Mylan launches three HIV generics in Canada

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Mylan launches three HIV generics in Canada

Genéricos/Novedades | Posted 15/09/2017 0 Post your comment

US generics giant Mylan Pharmaceuticals (Mylan) announced on 10 August 2017 that it had launched three generic HIV drugs in Canada, after having received final approval for the products from Health Canada.

The products include Mylan-Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg, which is a generic version of Truvada from Gilead Sciences. The second product is Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg, 200 mg and 300 mg is a generic alternative to Atripla, which is originally made by Bristol-Myers Squibb/and Gilead Sciences. The third product is Mylan-Tenofovir Disoproxil 300 mg, which is a generic alternative to Viread, also originally made by Gilead Sciences.

All three products are indicated for the treatment of HIV infections and, in addition, Viread is also indicated for the treatment of chronic Hepatitis B virus infections.

Approximately 37 million people globally are living with HIV/AIDS today. Mylan says that it has invested US$250 million in expanding its antiretroviral (ARV) production capacity, enabling the company to produce four billion ARV tablets and capsules every year.

Mylan’s Chief Commercial Officer Tony Mauro said that ‘Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS’. He added that ‘More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we're proud to further expand access to such medicines in Canada’.

Mylan also recently received prequalification status from the World Health Organization (WHO) for the first generic drug to treat hepatitis C. The antiviral agent sofosbuvir will be manufactured at a lower cost by Mylan in order to improve access to treatment in developing countries [1].

Reference
1. GaBI Online - Generics and Biosimilars Initiative. WHO prequalifies first generic hepatitis C drug [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Sep 15]. Available from: www.gabionline.net/Generics/General/WHO-prequalifies-first-generic-hepatitis-C-drug

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Mylan